Skip to content
OpenCapital
Get started

Viatris VTRS Cumulative Gross Losses and Impairments

Discontinued — last reported Q4 '23

Cumulative Gross Losses and Impairments at other companies

Merck & Co. logo
Merck & Co.MRK
$531M0.0%

Segments

By segment

See full
Developed Markets Segment$3.19B—
Japan, Australia and New Zealand Segment$651.8M0.0%
Emerging Markets Segment$499M0.0%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairedAccumulatedImpairmentLoss.

The official record: Viatris’s 10-Q, filed November 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Viatris's cumulative gross losses and impairments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's cumulative gross losses and impairments?
Viatris (VTRS) reported cumulative gross losses and impairments of $124M in Q4 2023.
What is the long-term trend for Viatris's cumulative gross losses and impairments?
Over 2 years (2020 to 2023), Viatris's cumulative gross losses and impairments has grown at a -43.2% compound annual growth rate (CAGR), from $385M to $124M.
What does cumulative gross losses and impairments mean?
This metric aggregates all unrealized losses and recognized impairment charges on investment securities that have not yet been realized through a sale. It provides a comprehensive view of the negative valuation adjustments impacting the bank's equity. It is a key indicator of the credit and market risk embedded in the bank's long-term holdings.